Forbes contributors publish independent expert analyses and insights. Sai writes about healthcare, innovation and technology. This voice experience is generated by AI. Learn more. This voice ...

I have been covering the Swiss-based gene therapy specialist drug developer CRISPR Therapeutics AG (CRSP) in notes for Seeking Alpha since my first post on the company all the way back in May 2021, ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

In a study published in Nature Communications titled “Construction of multi-targeted CRISPR libraries in tomato to overcome functional redundancy at genome-scale level,” researchers from Tel Aviv ...